India has emerged as one of the world's leading destinations for CAR T-cell therapy, combining internationally trained specialists, JCI-accredited hospitals, and treatment costs up to 90% lower than the US or UK.
In this guide, we compare the best CAR T-cell therapy hospitals in India by accreditation, available products, and success rates, list the top specialist doctors, and walk you through exactly how to choose the right centre for your specific cancer type whether that's leukemia, lymphoma, or multiple myeloma.
What Is CAR T-Cell Therapy?
CAR T-cell therapy is an advanced immunotherapy where a patient's own T-cells are genetically engineered to recognize and destroy cancer cells offering long-term remission for blood cancers that no longer respond to chemotherapy or radiation.
For a detailed overview of how it works, eligibility criteria, and complete cost breakdown, see our dedicated guide: CAR T-Cell Therapy Cost in India
How Does CAR T-Cell Therapy Work?
The treatment involves four key steps:
- T-cell collection (leukapheresis): Blood is drawn and T-cells are separated, typically over 3-5 hours.
- Genetic engineering: T-cells are sent to a certified lab where they are modified to express chimeric antigen receptors (CARs) targeting cancer-specific proteins.
- Expansion & infusion: Modified cells are multiplied over 3-4 weeks, then infused back into the patient after a short course of conditioning chemotherapy.
- Monitoring: Patients remain in hospital for 25-30 days to manage potential side effects, particularly cytokine release syndrome (CRS).
Conditions Treated Using CAR T-Cell Therapy
CAR T-cell therapy has shown remarkable success in treating certain blood cancers, particularly in patients with relapsed or refractory disease.
The therapy is US FDA-approved for:
Acute Lymphoblastic Leukemia (ALL)
- Most effective in children and young adults.
- Studies report remission rates as high as 80-90% in certain cases [1][2].
Non-Hodgkin’s Lymphoma (NHL)
- Effective against aggressive forms like diffuse large B-cell lymphoma (DLBCL).
- Nearly 50% of patients achieve long-term remission [3].
Multiple Myeloma
- Targets the BCMA antigen on myeloma cells.
- Trials show significant response rates even in heavily pretreated patients [4].
Emerging research is exploring the use of CAR T-cell therapy in solid tumors, autoimmune diseases, and certain infections, expanding its potential applications.
Wondering if CAR T-cell therapy is suitable for your condition? Contact us to discuss your treatment options with leading specialists in India.
We Handle the Planning
You Focus on Recovery
From Medical Visa assistance to airport pick-up and local stay, HOSPIDIO manages your entire medical trip.
Tell Us About Your Need
Free case review. Confidential. No obligation.When Is CAR T-Cell Therapy Used?
CAR T-cell therapy has emerged as a revolutionary treatment, especially for certain cancers that are resistant to conventional therapies. Below is a detailed explanation of when CAR T-cell therapy is used, considering various circumstances and patient conditions.
1. Relapsed or Refractory Blood Cancers (Leukemia and Lymphoma)
CAR T-cell therapy is most commonly used for blood cancers, particularly in patients with leukemia and lymphoma that do not respond to traditional treatments like chemotherapy or radiation. It is especially beneficial for:
- Acute Lymphoblastic Leukemia (ALL): This is a type of cancer that affects the blood and bone marrow, and it predominantly impacts children. CAR T-cell therapy has shown remarkable success in treating relapsed or refractory ALL, which means that the cancer has either returned after treatment or did not respond to initial therapies. Specifically, Kymriah (tisagenlecleucel) is FDA-approved for children and young adults with relapsed/refractory B-cell ALL.
- Chronic Lymphocytic Leukemia (CLL): CLL, a type of cancer that affects the blood and bone marrow, can be treated with CAR T-cell therapy when it no longer responds to chemotherapy. This is typically after multiple rounds of treatment, where other options have failed.
- Non-Hodgkin Lymphoma (NHL): CAR T-cell therapy has been particularly effective for diffuse large B-cell lymphoma (DLBCL), a type of aggressive NHL. After first-line treatments, including chemotherapy, fail, patients can benefit from CAR T-cell therapy, with significant improvements in survival rates. Yescarta (axicabtagene ciloleucel) and Kymriah are FDA-approved for this condition.
In these cases, CAR T-cell therapy offers a new avenue of hope for patients who have exhausted other treatment options.
2. Relapsed or Refractory Multiple Myeloma
Multiple myeloma is a cancer of plasma cells in the bone marrow. Although this cancer is often treatable, it can relapse after initial treatments, and some patients may develop a form that does not respond well to chemotherapy or other therapies. In such cases, CAR T-cell therapy is an emerging treatment option. Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel) are FDA-approved CAR T-cell therapies for relapsed or refractory multiple myeloma.
These therapies have shown promising results in clinical trials, leading to long-term remissions in some patients who did not respond to other treatments. The use of CAR T-cells is particularly valuable when there are few remaining treatment options.
3. Conditions with Specific Targetable Antigens
CAR T-cell therapy can also be used in conditions where there are specific, targetable antigens on the surface of cancer cells. For example:
- B-cell Malignancies: A variety of cancers involving B-cells, such as B-cell lymphomas or leukemia, can be treated with CAR T-cells targeting CD19, a protein commonly expressed on the surface of B-cells. CD19-targeting CAR T-cells have already demonstrated success in treating blood cancers, and trials are exploring their potential for other cancers expressing similar antigens.
- CD22+ Malignancies: In some blood cancers, CAR T-cells targeting CD22 (a different protein found on B-cells) have shown promise, particularly in cases where CD19-targeting therapies have failed.
4. Patients Who Have Failed Traditional Treatment Regimens
CAR T-cell therapy is also considered for patients who have undergone various forms of conventional treatment (e.g., chemotherapy, radiation, targeted therapies) but have not had a positive response or have relapsed. In these cases, it serves as a next-step option to potentially overcome resistance to existing therapies.
Advantages of CAR T-Cell Therapy
CAR T-cell therapy is a transformative approach to cancer treatment, offering several distinct benefits:
- High remission rates: 70–90% of eligible patients with blood cancers achieve remission, including those who failed multiple prior treatments.
- Precision targeting: CAR T-cells attack cancer cells while leaving healthy tissue largely unaffected, unlike chemotherapy or radiation.
- Long-term protection: Modified T-cells can remain active in the body for years, reducing the risk of cancer recurrence.
Learn how CAR T-cell therapy can benefit you. Contact us for expert guidance.
Cost of CAR T-Cell Therapy in India
One of the most significant advantages of seeking CAR T-cell therapy in India is its cost-effectiveness.
Average Cost:
CAR T-cell therapy in India costs approximately $45,000-$85,000 for imported therapies (Kymriah, Yescarta), and around $47,000-$50,000 for India's indigenous NexCAR19, making it 80–90% more affordable than the same treatment in the US ($400,000–$500,000). For a full cost breakdown by drug type, city, and inclusions/exclusions, see our detailed guide: CAR T-Cell Therapy Cost in India.
Success Rate of CAR T-Cell Therapy
CAR T-cell therapy has demonstrated remarkable success in treating certain types of cancers, particularly blood cancers like leukemia, lymphoma, and multiple myeloma. While outcomes can vary based on factors like cancer type, stage, and patient health, here’s a breakdown of its success rates:
Leukemia (Acute Lymphoblastic Leukemia - ALL)
- Success Rate: Up to 85-90% complete remission in pediatric and young adult patients with relapsed or refractory ALL.
- Statistics: In clinical trials, CAR T-cell therapy has shown long-term survival in 60-70% of patients after one year.
Lymphoma (Diffuse Large B-Cell Lymphoma - DLBCL)
- Success Rate: Around 40-50% of patients achieve durable remission.
- Key Insight: Even for patients who do not fully respond, CAR T-cell therapy often leads to significant tumor shrinkage.
Multiple Myeloma
- Success Rate: Early trials report response rates of 70-90% for relapsed or refractory multiple myeloma.
- Potential: These results are highly promising, especially for patients who have exhausted other treatment options.
Key Factors Affecting Success Rates
- Cancer Stage: Earlier-stage cancers tend to respond better than advanced or metastatic cancers.
- Patient Health: General fitness, immune system strength, and prior treatments influence outcomes.
- Therapy Design: Newer generations of CAR T-cells with dual targets or enhanced persistence have improved success rates.
Regulatory and Approval Aspects of CAR T-Cell Therapy in India
India is rapidly advancing in the field of CAR T-cell therapy, supported by initiatives from government and private institutions:
Regulatory Framework:
- The Central Drugs Standard Control Organization (CDSCO) has approved CAR T-cell therapy for specific indications.
- Clinical trials are ongoing to expand its applicability.
Pioneering Institutions:
- Tata Memorial Hospital and AIIMS are leading research efforts to make CAR T-cell therapy accessible to more patients. However, now the therapy is available at all major hospitals in India, including Fortis Hospital, Artemis Hospital, Max Hospital etc.
- Partnerships with global biotech companies are facilitating technology transfer and training programs [8].
India’s progressive regulatory environment ensures that patients receive globally recognized treatment standards at competitive costs.
Why Choose India for CAR T-Cell Therapy?
India has become a global hub for medical tourism, attracting patients from all over the world for a wide variety of medical treatments, including advanced therapies like CAR T-cell therapy. As a rapidly developing nation with an exceptional healthcare infrastructure, India offers several compelling reasons why patients from across the globe are opting for CAR T-cell therapy here.
World-Class Expertise and Highly Qualified Medical Professionals
One of the primary reasons to choose India for CAR T-cell therapy is the expertise of its medical professionals. India is home to a vast number of internationally trained oncologists, hematologists, and immunologists who have extensive experience in advanced treatments like CAR T-cell therapy. Many of these professionals have trained in top medical institutions abroad, including the US, the UK, and Europe, and bring that experience back to India to offer cutting-edge care.
Indian doctors are often involved in international research and clinical trials, meaning that they are at the forefront of global developments in cancer treatment, including immunotherapies like CAR T-cells. Hospitals and medical centers in India offer access to these skilled professionals, who are capable of delivering the latest treatments with a personalized approach.
Cost-Effectiveness and Affordability
One of the most significant advantages of choosing India for CAR T-cell therapy is the cost-effectiveness. Medical treatments, particularly innovative therapies like CAR T-cells, are typically very expensive in developed countries. For instance, CAR T-cell therapy in the United States or Europe can cost anywhere from $300,000 to $500,000 or more, depending on the treatment plan and associated costs.
In contrast, in India, the cost of CAR T-cell therapy can be significantly lower — often as much as 60-70% less than in Western countries. This reduction in cost does not come at the expense of quality; Indian hospitals offering CAR T-cell therapy have the same international standards of care and use cutting-edge technology. This makes India an attractive option for patients who want access to high-quality healthcare without the burden of overwhelming medical expenses.
State-of-the-Art Healthcare Infrastructure
India boasts an impressive network of healthcare facilities, including world-class hospitals, specialized cancer centers, and research institutions. Many of these hospitals are accredited by international organizations such as the Joint Commission International (JCI) and the National Accreditation Board for Hospitals & Healthcare Providers (NABH). These accreditations ensure that hospitals meet the highest standards of care, patient safety, and quality of services.
The country has a rapidly expanding healthcare sector with cutting-edge medical technologies. Hospitals in India are equipped with the latest infrastructure and treatment modalities for CAR T-cell therapy, including specialized laboratories for cell therapy, advanced diagnostic imaging, and the capability to perform genetic testing to tailor CAR T-cell therapy to the patient’s specific needs.
Advanced Research and Clinical Trials
India is not just a provider of medical treatments but also a center for medical research and clinical trials. Many top hospitals and medical institutions in India are involved in research related to CAR T-cell therapy and other innovative cancer treatments. This ensures that patients are receiving the most advanced, evidence-based therapies available.
Patients who come to India for CAR T-cell therapy can be treated with the latest research-backed protocols, and in some cases, they may even have access to clinical trials for new and experimental therapies that are not yet widely available in other parts of the world.
Low Cost of Living and Comfortable Recovery Environment
In addition to lower medical costs, India also offers a low cost of living compared to Western countries. For international patients, this means that their overall stay in India, including accommodation, food, and transportation, will be much more affordable.
Many hospitals in India also provide dedicated services for international patients, including help with travel arrangements, visa processing, and concierge services. Patients and their families can stay in comfortable, cost-effective accommodations near the hospital, making it easier for them to focus on recovery without the financial strain that often accompanies medical treatment abroad.
Comprehensive Multilingual Support with English Widely Spoken
Language barriers can often be a concern for international patients seeking treatment abroad. However, India offers a major advantage in this regard. English is widely spoken across the country, especially in the healthcare sector. Doctors, nurses, and medical staff at leading hospitals are fluent in English, and communication is seamless, making the treatment experience much more comfortable for English-speaking patients.
In addition to English, India is a multilingual country, with major languages such as Hindi, Bengali, Tamil, Telugu, and others being spoken. Hospitals that cater to international patients often provide language interpretation services, ensuring that patients from non-English-speaking countries feel at ease and receive the care they need in their native language.
Quick Access to Treatment and Minimal Waiting Time
In many Western countries, patients often face long waiting periods before they can receive cutting-edge treatments like CAR T-cell therapy, particularly for rare or complex cancers. In India, however, the waiting times are often shorter, and patients can receive quick access to the therapy they need. With the widespread availability of specialized cancer centers and expertise in CAR T-cell therapy, patients can avoid lengthy delays and start their treatment almost immediately after initial consultations and evaluations.
Holistic Care and Post-Treatment Support
Indian hospitals also offer holistic care for cancer patients, including counseling, physiotherapy, and rehabilitation. This comprehensive approach ensures that patients are supported not only during the treatment process but also during recovery. After undergoing CAR T-cell therapy, patients benefit from a personalized follow-up care plan, which may include regular monitoring, psychological support, and physical rehabilitation to enhance recovery outcomes.
Growing International Recognition
India’s healthcare system is gaining global recognition for its excellence in specialized care. Many Indian hospitals have built partnerships with international healthcare organizations, attracting patients from across the world. The international recognition of India’s healthcare sector, combined with the expertise of its medical professionals, further boosts the trust international patients place in Indian medical institutions.
Planning to travel to India for CAR T-cell therapy? Let us assist you with end-to-end support.
Top CAR T-Cell Therapy Hospitals in India - Compared
| Hospital | City | Accreditation | CAR-T Products | International Patients/Year | Rating |
| BLK-Max Super Speciality | Delhi | JCI + NABH + NABL | Kymriah, NexCAR19 | 90k+ | 4.6 |
| Fortis Memorial Research Institute | Gurgaon | JCI + NABH + NABL | NexCAR19 | 72k+ | 4.6 |
| Medanta The Medicity | Gurgaon | JCI + NABH + NABL | Kymriah, NexCAR19 | 125k+ | 4.2 |
| Artemis Hospital | Gurgaon | JCI+ NABH + NABL | NexCAR19 | 35k+ | 4.1 |
| Kokilaben Dhirubhai Ambani | Mumbai | JCI + NABH+ NABL + CAP | NexCAR19 | 25k+ | 3.8 |
| Nanavati Max Hospital | Mumbai | JCI + NABH + NABL | NexCAR19 | 50k+ | 4.5 |
| Gleneagles Global Health City | Chennai | NABH + NABL + NABB | NexCAR19 | 55k+ | 4.7 |
How to Choose the Best CAR T-Cell Therapy Hospital in India
Choosing the right hospital for CAR T-cell therapy involves more than cost. Here are the key factors to evaluate:
- Experience with your specific cancer type Not all hospitals offer CAR-T for every indication. Confirm the hospital has performed CAR-T specifically for your cancer (ALL, DLBCL, myeloma, etc.) and ask for their case volume.
- Available CAR-T products Some hospitals offer only Kymriah; others also have Yescarta, Abecma, Carvykti, and the newer NexCAR19. Eligibility depends on your diagnosis and the DCGI-approved indication for each product.
- ICU and CRS management capability Cytokine Release Syndrome (CRS) is the most serious risk of CAR-T. Choose a hospital with a dedicated cellular therapy unit and a 24/7 ICU experienced in managing CRS and neurotoxicity.
- International patient infrastructure For international patients: look for hospitals with a dedicated international patient office, NABH or JCI accreditation, and experience coordinating medical visas, accommodation, and post-treatment follow-up.
- Proximity to specialized labs The genetic engineering of T-cells takes 3–4 weeks. Hospitals partnered with certified cell therapy labs (including those using NexCAR19 manufactured by ImmunoACT) can often deliver faster turnaround.
Best Doctors in India Specializing in CAR-T Therapy
India boasts a number of highly qualified and experienced specialists in CAR T-cell therapy, a cutting-edge treatment for various cancers, particularly blood cancers like leukemia and lymphoma. Below is a list of top doctors who are recognized for their expertise in CAR T-cell therapy, each bringing years of experience and a deep commitment to patient care.
1. Dr. Rahul Bhargava
Dr. Rahul Bhargava is a renowned hematologist and bone marrow transplant specialist at Fortis Memorial Research Institute in Gurugram. With extensive experience in hematology, he specializes in CAR T-cell therapy, bone marrow transplants, and other advanced treatments for hematologic malignancies. Dr. Bhargava has been involved in several landmark cases of CAR T-cell therapy in India, successfully treating patients with blood cancers such as leukemia and lymphoma. Known for his compassionate approach, Dr. Bhargava works closely with his patients, offering personalized treatment plans. He is highly regarded for his expertise in immunotherapy and is a key figure in advancing CAR T-cell therapy in India.
2. Dr. Akash Khandelwal
Dr. Akash Khandelwal is a consultant hematologist at Fortis Hospital in Shalimar Bagh, New Delhi, with specialization in oncology and immunotherapy. He is widely recognized for his work in CAR T-cell therapy and stem cell transplants for the treatment of blood cancers, including lymphoma and leukemia. Dr. Khandelwal has been at the forefront of CAR T-cell adoption in India and has treated numerous patients with advanced blood cancers. His meticulous approach and expertise in immunotherapy have earned him a reputation as one of the leading specialists in the field. He is also dedicated to educating and guiding patients and families through the complex treatment process.
3. Dr. Esha Kaul
Dr. Esha Kaul is a leading hematologist and oncologist at Max Super Speciality Hospital, Vaishali, who specializes in treating blood cancers using advanced therapies such as CAR T-cell therapy. With a focus on personalized medicine, Dr. Kaul is known for her expertise in developing tailored treatment plans that incorporate the latest in immunotherapy techniques. She has been involved in clinical trials and research, focusing on the safety and efficacy of CAR T-cell therapy. Dr. Kaul is highly regarded for her comprehensive care approach, guiding patients from diagnosis through treatment and recovery, ensuring they have the best outcomes possible.
4. Dr. Gaurav Dixit
Dr. Gaurav Dixit is a highly experienced oncologist and hematologist at Artemis Hospital in Gurugram, specializing in bone marrow transplant and CAR T-cell therapy for blood cancers. With years of clinical experience in immuno-oncology, Dr. Dixit is one of the leading specialists in CAR T-cell therapy, helping patients with refractory cancers such as acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma. His expertise extends beyond treatment, as he also conducts research to improve the outcomes of immunotherapy. Dr. Dixit is known for his compassionate care and for working closely with each patient to provide comprehensive support throughout the treatment journey.
5. Dr. Punit Jain
Dr. Punit Jain is a distinguished hematologist and oncologist at Apollo Hospital in Mumbai, specializing in CAR T-cell therapy, stem cell transplants, and immunotherapy for blood-related cancers. With a reputation for excellence in his field, Dr. Jain is one of the foremost experts in CAR T-cell therapy in India. His patient-centric approach and deep understanding of hematologic malignancies have made him a sought-after specialist for complex cases. Dr. Jain is known for his ability to offer innovative treatment options, utilizing CAR T-cell therapy as part of his comprehensive treatment plans to help patients with advanced blood cancers achieve remission. He is committed to improving patient outcomes and advancing the field of immuno-oncology through continuous research and clinical practice.
CAR T-cell therapy represents a significant leap forward in cancer treatment, offering hope to patients who have exhausted other options. India’s growing expertise in this field, coupled with its cost advantages and patient-centric approach, makes it an ideal destination for this cutting-edge therapy.
If you or a loved one is exploring CAR T-cell therapy, our team is here to guide you through every step of the journey. From selecting the right hospital to ensuring seamless travel and care, we are committed to supporting you in achieving the best possible outcome.
Contact us today to learn more about CAR T-cell therapy in India and how we can assist you.
Reference
- National Cancer Institute: CAR T-cell Therapy Overview
- The Lancet Oncology: CAR T-cell Success Rates in Lymphoma
- Journal of Hematology & Oncology: Advances in CAR T-cell Therapy for Blood Cancers
- AIIMS India: Ongoing Clinical Trials in CAR T-cell Therapy
- Stat News: CAR T-cell Therapy Cost Analysis and Affordability Globally
- Economic Times Health: Comparative Cost of CAR T-cell Therapy in India and Abroad
- Nature Reviews Clinical Oncology: Future Applications of CAR T-cell Therapy in Solid Tumors
- Tata Memorial Centre Reports: India’s Role in Advancing CAR T-cell Therapy
Recent Blogs
FAQs
Guneet Bhatia is the Founder of HOSPIDIO and an accomplished content reviewer with extensive experience in medical content development, instructional design, and blogging. Passionate about creating impactful content, she excels in ensuring accuracy and clarity in every piece. Guneet enjoys engaging in meaningful conversations with people from diverse ethnic and cultural backgrounds, enriching her perspective. When she's not working, she cherishes quality time with her family, enjoys good music, and loves brainstorming innovative ideas with her team.
Sasmita Bal is a Digital Marketing and Content Specialist at HOSPIDIO with expertise in SEO and international healthcare content. She reviews published material to ensure it is optimized for search visibility and relevant to the needs of international patients seeking treatment in India. All content she reviews is authored and clinically approved by the Founder of HOSPIDIO and relevant medical specialists prior to publication.